ReviewPharmaceuticals (Basel, Switzerland)2023
Recent Progress of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers as Ocular Drug Delivery Platforms.
Review in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Dietary and Formulation Potential of Natural Oils and Fats in Ocular Health and Disease: Mechanisms, Evidence, and Future Directions.Nutrients · 2026Review
- Nanoparticulate and Hydrogel Vehicles for Stimuli-Responsive and Sustained Controlled Release of Active Pharmaceutical Ingredients.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Article
- Kaempferol-loaded solid lipid nanoparticles attenuate cartilage degradation and inflammation by modulating the expression of pro and inflammatory cytokines, MMP-13 and oxidative stress markers in adjuvant induced arthritic rats.Inflammopharmacology · 2026Article
- Nanocarrier-Based Ocular Drug Delivery Systems for Retinal Diseases: Therapeutic Potential.Life (Basel, Switzerland) · 2026Review
- Besifloxacin-Loaded Nanostructured Lipid Carrier for Ocular Delivery: Formulation Optimization, In Vitro Characterization, and Safety Assessment.AAPS PharmSciTech · 2026Article
- Ion-activated mucoadhesive in situ gel incorporating terbinafine-loaded NLCs promotes ocular penetration and retention for enhanced fungal keratitis therapy.Materials today. Bio · 2026Article
- Advances in RPGR gene therapy for X‑linked retinitis pigmentosa: From preclinical insights to clinical application (Review).International journal of molecular medicine · 2026Review
- Bridging Gaps in Fungal Keratitis Management: Novel Diagnostics, Drug Delivery Systems, and Gene Therapies.AAPS PharmSciTech · 2026Review
- Silk fibroin-coated resveratrol solid lipid nanoparticles for diabetic wound healing.Scientific reports · 2026Article
- Targeted RNA Degradation by RIBOTACs: A Novel Therapeutic Avenue for Ophthalmic Diseases.International journal of molecular sciences · 2026Review
- Brimonidine Beyond a Single Specialty: Pharmacological Profile, Dermatologic Applications, and Advances in Drug Delivery Systems.International journal of molecular sciences · 2026Review
- Advances in the management of ocular anterior segment diseases using biomaterials-based drug delivery systems.Journal of biomaterials applications · 2026Review
- An organoid-guided roadmap for precision delivery of epigallocatechin gallate in oral submucous fibrosis.Frontiers in bioengineering and biotechnology · 2026Review
- Exploration of recent advancements of nanoparticle-based therapeutics emphasis on diabetic-related chronic wound management: a comprehensive review.Archives of pharmacal research · 2026Review
- Therapeutic potential of curcumin in ophthalmic diseases: mechanisms and clinical applications.Journal of translational medicine · 2025Review
- Advances in nanostructured drug delivery systems for cardiovascular therapeutics.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Review
- Comprehensive insights into the role of nanocarriers in advancing azole-based ocular therapeutics.RSC advances · 2025Review
- In Situ Forming Poloxamer-Based Thermo-Sensitive Hydrogels for Ocular Application: A Focus on the Derivatives 407 and 188.Gels (Basel, Switzerland) · 2025Review
- Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Anticancer Phytochemical Delivery: Advances, Challenges, and Future Prospects.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sufficient ocular bioavailability is often considered a challenge by the researchers, due to the complex structure of the eye and its protective physiological mechanisms. In addition, the low viscosity of the eye drops and the resulting short ocular residence time further contribute to the observed low drug concentration at the target site. Therefore, various drug delivery platforms are being developed to enhance ocular bioavailability, provide controlled and sustained drug release, reduce the number of applications, and maximize therapy outcomes. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) exhibit all these benefits, in addition to being biocompatible, biodegradable, and susceptible to sterilization and scale-up. Furthermore, their successive surface modification contributes to prolonged ocular residence time (by adding cationic compounds), enhanced penetration, and improved performance. The review highlights the salient characteristics of SLNs and NLCs concerning ocular drug delivery, and updates the research progress in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.